Publications by authors named "A Madi Kassim"
Peripheral nerves promote mouse bone marrow regeneration by activating b2 and b3 adrenergic receptor signaling, raising the possibility that non-selective b blockers could inhibit engraftment after hematopoietic cell transplants (HCTs). We observed no effect of b blockers on steady-state mouse hematopoiesis. However, mice treated with a non-selective b blocker (carvedilol), but not a b1-selective inhibitor (metoprolol), exhibited impaired hematopoietic regeneration after syngeneic or allogeneic HCTs.
View Article and Find Full Text PDFBackground And Objectives: Sickle cell disease (SCD) is a hemoglobinopathy resulting in hemoglobin-S production, hemolytic anemia, and elevated stroke risk. Treatments include oral hydroxyurea, blood transfusions, and hematopoietic stem cell transplantation (HSCT). Our objective was to evaluate the neurologic relevance of these therapies by characterizing how treatment-induced changes in hemoglobin (Hb) affect brain health biomarkers.
View Article and Find Full Text PDFArticle Synopsis
- - Sickle cell disease (SCD) is the most prevalent inherited blood disorder, affecting primarily children in the U.S. and Europe, where treatments have improved their survival rates, but adults still face significant health risks and early death.
- - Recent FDA-approved genetic therapies have shown promise in reducing pain events associated with SCD, while allogeneic hematopoietic cell transplantation (alloHCT) offers a curative option, though both face challenges such as donor availability and serious health risks.
- - Advances in treatment methods are addressing these challenges, positioning both genetic therapies and alloHCT as potential cures, though genetic therapies are more expensive and may have serious long-term side effects compared to alloHCT.
Motivation: Post-translational modifications (PTMs) increase the diversity of the proteome and are vital to organismal life and therapeutic strategies. Deep learning has been used to predict PTM locations. Still, limitations in datasets and their analyses compromise success.
View Article and Find Full Text PDFArticle Synopsis
- The Blood and Marrow Transplant Clinical Trials Network is running a study to help kids ages 5 to almost 15 with sickle cell disease by using special stem cell transplants.
- They started by only allowing kids who had a clear stroke to join, but then they opened it up to others who had silent brain injuries or high-risk blood flow problems.
- They created different stages for kids to qualify based on serious health issues, like breathing problems or ongoing pain, to ensure the best chance for help in the trial.